Drug Profile


Alternative Names: CHIR-258; Dovitinib lactate; GFKI-258; Growth factor kinase inhibitor 258; TKI 258

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Academic and Community Cancer Research United; Georgetown University; National Cancer Institute (USA); Novartis; University of California, Davis; University of Texas M. D. Anderson Cancer Center; University of Virginia; Yonsei University Health System
  • Class Antineoplastics; Benzimidazoles; Lactates; Piperazines; Quinolones; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Type 3 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Adenocarcinoma; Breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Gastrointestinal stromal tumours; Haematological malignancies; Hepatocellular carcinoma; Malignant melanoma; Mesothelioma; Multiple myeloma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Solid tumours; Thyroid cancer; Urogenital cancer; Von Hippel-Lindau disease

Most Recent Events

  • 12 Jun 2017 The MD Anderson Cancer Center & Novartis complete a phase II trial for Prostate cancer (castration-resistant, metastatic) in USA (NCT00831792)
  • 01 Nov 2016 Novartis completes a phase II/III trial in Solid tumours in USA, Denmark, Italy, Japan, Netherlands, Spain, Austria and Belgium (PO) (NCT02116803)
  • 26 May 2016 Novartis terminates a phase II trial in Breast cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA, Argentina, Austria, Belgium, Brazil, France, Hungary, Italy, Netherlands, Peru, Poland, Russia, South Africa, Spain and Taiwan due to low and slow enrolment (NCT01528345)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top